Glial cell-derived neurotrophic factor receptor alpha-like (GFRAL) (GFRAL)

The **growth/differentiation factor 15 receptor**, more accurately named **glial cell-derived neurotrophic factor receptor alpha-like (GFRAL)**, is a membrane-bound protein primarily expressed in specific regions of the brainstem—the area postrema and nucleus tractus solitarius. It serves as the exclusive high-affinity signaling partner for growth/differentiation factor 15 (**GDF15**) under physiological conditions. Upon binding its ligand, GFRAL forms a complex with RET proto-oncogene co-receptor to activate intracellular pathways such as ERK and AKT/PKB but does not engage canonical TGF-beta signaling. This axis plays a critical role in regulating food intake and body weight during states of tissue damage or systemic illness—often mediating anorexic responses seen in chronic diseases like cancer. Elevated circulating levels of GDF15 signal through this pathway to suppress appetite—a mechanism now being targeted therapeutically for conditions such as cancer cachexia. While no drugs currently target **GFRAL itself**, anti-GDF15 therapies are advancing clinically. The discovery that **GFRAL is restricted almost exclusively to certain neurons within the adult brainstem underscores its specialized function in non-homeostatic energy balance regulation**, distinguishing it from other widely expressed receptors involved in metabolism.

Other names

GDNF family receptor alpha-likeGrowth/differentiation factor 15 receptorGDF15 receptor

Drugs targeting this pathway generally act by: 1. Blocking GDF15 from binding to its receptor GFRAL, thereby preventing downstream signaling that leads to anorexia/cachexia. 2. Modulating appetite regulation pathways in the brainstem by interfering with ligand-receptor interaction.